Filing Flows › Gilead Sciences (GILD) › Q3 2026 › vs Q2 2026
Gilead Sciences (GILD) Q3 2026 vs Q2 2026 (quarter over quarter)
Gilead Sciences's revenue rose $497M (+6%) from $7.8B in Q2 2026 to $8.3B in Q3 2026. Operating margin 41.7% against -133.2% (+174.9 pts).
Gilead Sciences, Q3 2026: revenue $8.3B (+7% year over year), operating margin 41.7%, net earnings $2.4B, operating cash flow $5.0B. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 41.7% | -133.2% | +174.9 pts |
| Net margin | 29.3% | -134.5% | +163.8 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $8.3B | $7.8B | $497M | +6% |
| Operating profit | $3.5B | −$10.4B | $13.9B | — |
| Costs & expenses | $4.8B | $18.2B | −$13.4B | -73% |
| Pre-tax earnings | $3.1B | −$10.3B | $13.3B | — |
| Other expense, net | $399M | −$140M | $539M | — |
| Cost of revenue | $1.6B | $1.6B | −$8.0M | -0.5% |
| Research & development | $1.6B | $1.8B | −$156M | -9% |
| SG&A | $1.6B | $1.9B | −$280M | -15% |
| Other operating costs | $18.0M | $12.9B | −$12.9B | -100% |
| Net earnings | $2.4B | −$10.5B | $12.9B | — |
| Income tax | $634M | $242M | $392M | +162% |
| Depreciation | $132M | $98.0M | $34.0M | +35% |
| Share-based compensation | $234M | $231M | $3.0M | +1% |
| Working capital & other | $2.2B | $13.7B | −$11.5B | -84% |
| Operating cash flow | $5.0B | $3.6B | $1.5B | +41% |
Questions
How much did Gilead Sciences's revenue grow quarter over quarter in Q3 2026?
Gilead Sciences's revenue rose $497M (+6%) from $7.8B in Q2 2026 to $8.3B in Q3 2026. Operating margin 41.7% against -133.2% (+174.9 pts).